{"entity":{"id":"nct07178717","kind":"trial","name":"A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W","aka":["REFISH"],"tldr":"A phase 2 trial of bevacizumab (glioblastoma use) and encorafenib in colorectal cancer, run by Vall d'Hebron Institute of Oncology, not yet recruiting.","summary":"A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations is a phase 2, interventional study registered as NCT07178717 by Vall d'Hebron Institute of Oncology, with a registry enrolment figure of 25 participants, started 2025-10 and due to reach its primary completion in 2028-02. Interventions recorded: Rechalange with bevacizumab + encorafenib. Conditions listed: Colo-rectal Cancer. Primary outcome: Progression free survival. Colorectal eligibility wording from the registry: \"5 x ULN is allowed if direct (conjugated) ≤1\". Sites: Spain. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07178717","url":"https://clinicaltrials.gov/study/NCT07178717"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","braf-v600e-colorectal"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":["bevacizumab-glioma","encorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07178717","phase":"2","setting":"A Phase 2, Single-Arm Study of Encorafenib Plus Cetuximab as Rechallenge Treatment of BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations: the RefIsh Trial","sponsor":"Vall d'Hebron Institute of Oncology","enrolled":25,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07178717/","neighbours":{"cancer":[{"id":"braf-v600e-colorectal","kind":"cancer","name":"BRAF V600E-mutant colorectal cancer","route":"/cancers/braf-v600e-colorectal/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"bevacizumab-glioma","kind":"drug","name":"Bevacizumab (glioblastoma use)","route":"/drugs/bevacizumab-glioma/"},{"id":"encorafenib","kind":"drug","name":"Encorafenib","route":"/drugs/encorafenib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}